Premier Alternatives

Genomics

Oxford, United Kingdom · Founded 2014 · Privately Held (backing)

Developer of a genetic inference technology designed to lead the genomic transformation by finding new drug targets for serious diseases. Genomics is based in Oxford, United Kingdom and was founded in 2014. Its last known valuation is $162 million. It has raised $142 million.

Last price · $/share
—
Implied valuation
$161.6M
Total raised
$142.2M
Last round
—

Genomics key facts

  • Developer of a genetic inference technology designed to lead the genomic transformation by finding new drug targets for serious diseases.
  • Genomics’s last known valuation is $161.6M.
  • It has raised $142.2M; the latest was Later Stage VC ($44.0M) in Nov 2024.
  • Notable investors include F-Prime Capital, Eight Roads, Salica Investments, University of Oxford, Oxford Science Enterprises — 16 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Genomics with a free account
  • ·The complete investor list: 16 names
  • ·Watch Genomics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Genomics funding rounds

No rounds on record

No funding rounds for Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Genomics valuation

Genomics's last known valuation is $162 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

Genomics investors

16 investors are on record for Genomics, including F-Prime Capital, Eight Roads, Salica Investments and University of Oxford. By type, the record holds 4 venture capital firms and 2 hedge funds.

About Genomics

Developer of a genetic inference technology designed to lead the genomic transformation by finding new drug targets for serious diseases. The company uses an analytical platform for genomic sequence data investigation and consultancy, which maximizes the impact of DNA sequencing and helps to identify individuals at risk of particular diseases, enabling pharmaceutical businesses to avail a genomic engine that de-risks the drug development process and provides improved healthcare.

Sector
Healthcare
HQ
Oxford, United Kingdom
Founded
2014
Employees
195
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$161.6M

Genomics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.